Allergy Research Group Inc. offers nutritional supplement products. It offers amino acids, antioxidant formulas, bioenergetics, bioflavonoids, blood sugar, books, brain, cardiovascular, comprehensive formulas, fatty acids, eye, gastric support, glandulars, and hormone products. Allergy Research Group also provides immune support, liver support, martin pall products, metabolic support, microbial balancers, minerals, multiples, musculoskeletal, probiotics, specialty products, vitamin B products, vitamin C products, and vitamin D, E, K products. The company was founded in 1979 and is headquartered in Alameda, California. As of September 9, 2008, Allergy Research Group Inc. operates as a subsidiary of KI NutriCare, Inc.

Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), with operations in more than 50 countries, it helps drug and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its Innovex subsidiary is a contract sales organization providing sales personnel to promote approved products. An investment group led by founder and CEO Dennis Gillings owns the company.

Sinclair Pharma can help those with itchy skin or bleeding gums. The specialty pharmaceutical development company acquires oral health and dermatology companies that have already begun developing products and turns them into new lines or line extensions for commercial sale. Its top sellers include Aloclair for mouth ulcers, Decapinol for gingivitis, and Atopiclair for ezcema. It has a sales presence in the UK, France, Italy, Portugal, and Spain, with marketing partners in more than 80 countries. When former CEO Michael Flynn led a management buy-in in 2000, Sinclair's strategy shifted from being a traditional early research and development company to an acquisition vehicle of late-stage development products.

ACON Laboratories, Inc. company was founded in 1995 and is based in San Diego, California. ACON Laboratories has a contracted manufacturing facility located in Hangzhou, China. ACON Laboratories, Inc. engages in the custom product design and contract manufacturing of diagnostic healthcare products. It offers rapid test products for fertility, infectious diseases, and drugs of abuse, as well as provides tumor markers, cardiac markers, lateral flow immunoassay products, blood glucose monitoring systems, and urinalysis products. The company also provides urinalysis reagent strips, breath alcohol detectors, antibodies test kits, urine analyzers, antibody enzyme immunoassay (EIA) test kits, hepatitis B virus EIA test kits, hepatitis C virus antibody EIA test kits, syphilis antibody EIA test kits, antigen test devices, gonorrhea and Chlamydia test strips, gonorrhea test strips, and tuberculosis test devices. In addition, it offers diagnostic rapid test products, which are used to detect pregnancy, ovulation, menopause, HCV, HIV, helicobacter pyloris, malaria, and dengue. The company supplies its products to hospitals, clinical laboratories, blood banks, and consumer outlets. ACON Laboratories sells its products through independent medical distributors in Asia, the Middle East, Africa, the Russian Federation, and Latin America.

Imperial Ginseng Products company cultivates more than 550 acres of North American ginseng root used in traditional Chinese medicine. The company operates a farm in Ontario, Canada, where the root is grown for three or four years (each year increases yield and value), harvested, and dried. Imperial Ginseng Products sells the dried root to buyers in North America and Asia, who then turn it into prepared remedies. CDS & Co owns 55% of the company, while co-chairmen Hugh Cartwright and Stephen McCoach and director Maurice Levesque together hold nearly 40%.

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

BBI Holdings Plc, through its subsidiaries, engages in the development and manufacture of noninvasive lateral flow tests, and the distribution of diabetes products in the United Kingdom and internationally. It operates in three divisions: Diagnostics, Enzymes, and Healthcare. The Diagnostics division involves in the development, manufacture, supply of reagents. The Enzymes engages in the manufacturer and supply of specialist natural enzymes to the medical diagnostics industry. The Healthcare segment involves in the sale and marketing of GlucoGel, a dextrose gel used by diabetes patients when they experience hypoglycaemia; and development of diabetes care product portfolio. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom. As of February 12, 2008, BBI Holdings plc operates as a subsidiary of Inverness Medical Innovations Inc.

American Bio Medica Corporation develops, manufactures, and sells immunoassay diagnostic test kits for the point of collection testing (POCT) for drugs of abuse in North America, Europe, the Asia/Pacific Rim, Africa, and South America. Its products include Rapid Drug Screen, a POCT kit to detect the presence or absence of 2 to 10 drugs of abuse in a single urine specimen; Rapid One, which screens for the presence or absence of a single drug of abuse in a urine specimen; Rapid TEC that contains 1 or 2 drug testing strips to test for 2 to 5 drugs of abuse in a single urine specimen; RDS InCup, a POCT for 2 to 12 drugs of abuse that incorporate collection and testing of sample in a device; Rapid TOX, a drug screen that detects 2 to 10 drugs of abuse in a single urine specimen; and Rapid TOX Cup, a POCT for 2 to 14 drugs of abuse that incorporate collection and testing of sample in a single device.American Bio Medica Corporation company’s products also include OralStat, a POCT system to detect drugs of abuse in oral fluids; OralStat EX, an oral fluid POCT for point of collection testing and confirmation testing; and Rapid STAT, an oral fluid POCT. In addition, it offers Rapid Reader, a compact and portable device that captures a picture of the test results on an ABMC drug screen. Further, American Bio distributes various POCTs to detect the presence or absence of adulterants, alcohol, and nicotine; and provides bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It offers products for employers, law enforcement, government, health care, laboratory, and education professionals to test for cocaine, THC, opiates, amphetamines, PCP, benzodiazepines, methamphetamines, barbiturates, tricyclic antidepressants, methadone, oxycodone, propoxyphene, and buprenorphine. The company was formerly known as American Micro Media, Inc and changed its name to American Bio Medica Corporation in September 1992. The company was founded in 1986 and is based in Kinderhook, New York.

American Oriental Bioengineering, Inc. (AOB) is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. The Company’s business comprises prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA). The Company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and cities in China. During the year ended December 31, 2008, AOB marketed over 60 pharmaceutical products in China. On October 18, 2008, the Company acquired Nuo Hua Investment Company Limited. On October 20, 2008, the Company acquired GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd.

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.